It can be tough to find public anti-aging companies to invest in, but it’s certainly possible with a little time and effort.
The global anti-aging products and therapies market is expected to grow 54 percent to reach US$216.52 billion by 2021. That’s up from $140.3 billion just a few years ago in 2015.
Calico, Human Longevity and Elysium are some of the big names that dominate headlines in the field, but for investors looking for other opportunities there are more options to look at.
The world’s population is always growing older, and the need to look and feel young as long as possible gives life science companies an increased interest in devices and anti-aging technologies, including items focused on health preservation.
Beyond the aesthetics of aging, “age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits,” says a study titled “The Business of Anti-Aging Science.” It continues, “[s]ome therapeutic approaches — direct-to-consumer nutraceuticals and trial-tested scientific diets — do not require FDA approval, which can significantly reduce their time to market.”
Here the Investing News Network provides a brief overview of eight publicly traded anti-aging companies, with options both in the small- and large-cap sectors. The anti-aging companies are listed in descending order of market cap; all prices are in US dollars and were taken from Google Finance at market close on November 7, 2018.
1. Zimmer Biomet (NYSE:ZBH)
Market cap: $24.1 billion; current share price: $118.16
First on this list of anti-aging companies is Zimmer Biomet. Its focus is on musculoskeletal healthcare. The company designs and manufactures personalized joint replacement technologies whose uses include orthopedic reconstruction, sports medicine, biologics, extremities and trauma, spine, craniomaxillofacial and thoracic products and dental implants.
Near the end of May, Zimmer received 510(k) clearance from the FDA for its Zyston Strut Open Titanium Interbody Space System. It is the company’s first titanium spinal implant manufactured via a 3D printing process. In July, Zimmer released its Q2 results, citing $2 billion in net sales for the time period, which is a 3-percent increase year-on-year.
2. Nu Skin Enterprises (NYSE:NUS)
Market cap: $4.04 billion; current share price: $72.82
Nu Skin Enterprises is a global direct-selling company that markets personal care and nutritional products in 53 markets across the world. Additionally, Nu Skin develops and distributes anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. One such anti-aging nutritional supplement is ageLOC R2, which is designed to recharge and renew the body.
At the end of April, the company put out its Q2 financial report, citing 28-percent growth in revenue year-on-year for a total of $704.2 million. Its customer base grew as well, rising to 1.1 million, which represents 8-percent growth.
3. Acorda Therapeutics (NASDAQ:ACOR)
Market cap: $987.19 million; current share price: $20.79
Third on this list of anti-aging companies is Acorda, which is developing therapeutics that restore function and improve the lives of people with neurological disorders. The company already has two marketed FDA-approved therapeutics, including Amypra® and Qutenza®.
In its Q2 financial results, announced in August, Acorda reported net sales from Ampyra® of $150.3 million and reiterated its guidance for the year at $330 to $350 million. The company also noted that its Inbrija™ product is currently under FDA review.
4. BioTime (NYSEAMERICAN:BTX)
Market cap: $266.44 million; current share price: $2.10
BioTime works in the fields of regenerative medicine, human embryonic stem cell technology and induced pluripotent stem cell technology. It develops therapies that are based on stem cell biology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury.
The company reported an expansion to its OpRegen Phase 1 clinical trial in dry-AMD by opening two additional US sites in May. In addition, BioTime reported in its Q2 results that it would be receiving $43 million from Juvenescence in exchange for 14.4 million shares of AgeX Therapeutics. Total revenue for the period was $2.5 million.
5. resTORbio (NASDAQ:TORC)
Market cap: $334.06 million; current share price: $11.91
Next on our list of anti-aging companies is resTORbio. This biopharmaceutical company is focused on helping people live longer. The company’s lead program is targeting the selective inhibition of TORC1, which is an evolutionary conserved pathway contributing to the decline in function of multiple organ systems, including the immune, cardiac and neurological systems.
In August, the company released its Q2 financial results, providing an update on a Phase 2b trial for its RTB101 product. It reported positive results and the company intends to hold a meeting with the FDA in Q4 of this year.
6. CohBar (NASDAQ:CWBR)
Market cap: $167.73 million; current share price: $3.95
This company is taking a different approach to age-related disease through the research and development of mitochondria-based therapeutics, an emerging class of drugs. A novel group of peptides encoded within the mitochondrial genome has been shown to regulate metabolism and cell death.
In Q2, CohBar increased its R&D expenses from $1.27 million to $1.83 million from the same quarter the previous year. This was due to costs related to its clinical and investigational drug application activities and an increase in stock-based compensation for option grants made.
7. Proteostasis Therapeutics (NASDAQ:PTI)
Market cap: $263 million; current share price: $6.91
This biopharmaceutical company has a focus on identifying therapies that restore protein function. Proteostasis Therapeutis is developing small-molecule therapeutics to treat cystic fibrosis, a disease caused by dysfunctional protein processing; it has a partnership with Astellas Pharma (TSE:4503) to research and identify therapies targeting the unfolded protein response pathway.
In May, the company announced the formation of an independent steering committee of lead experts to advise on a Phase 3 global clinical development program for PTI-428, the company’s candidate for cystic fibrosis transmembrane conductance regulatory amplifier. In June, the company announced positive results from an ongoing Phase 1 study of its drug PTI-801 for patients with cystic fibrosis. In August, Proteostasis released its Q2 report, citing a net loss of $1.5 million.
8. Prana Biotechnology (NASDAQ:PRAN)
Market cap: $15.84 million; current share price: $1.77
Last on this list of anti-aging companies is Prana Biotechnology. Based in Australia, Prana Biotechnology is a development-stage medical biotech company that’s engaged in research related to Alzheimer’s disease, Huntington disease, Parkinson’s disease and other age-related degenerative disorders.
The company’s lead drug candidate, PBT2, is intended to treat Alzheimer’s and Huntington’s diseases, and other products are still in the preclinical stage. In June, the company released its fiscal year report, citing revenue of AU$201,174 for the year, representing an increase of 51.9 percent compared with the previous year. The firm also increased its research and development budget to AU$6.6 million, up 17 percent from 2017.
Global X Longevity Thematic ETF (NASDAQ:LNGR)
Net Assets: 14.7 million; current share price: $20.75
Although it is not a single company focused on the business of longevity or anti-aging, investors should take note of the Global X Longevity Thematic ETF. Started in May 2016, the ETF provides investors with access to companies focused on increasing lifespans or extending quality of life in advanced age.
The ETF has 100 holdings, 33.54 percent of which are companies in the biotechnology space, while 34.86 percent are in healthcare equipment. The large majority of this ETF’s holdings are in the large-cap space.
Which anti-aging companies are you interested in? Tell us in the comments.
This is an updated version of an article originally published by the Investing News Network in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Amanda Kay, hold no direct investment interest in any company mentioned in this article.